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ABSTRACT 
Continuous pharmaceutical manufacturing (CPM) is a promising new paradigm to produce active 
pharmaceutical ingredients (APIs), allowing reduced equipment dimensions, lower waste production 
and energy consumption, and safer operation in comparison to the industrially dominant batch 
methods. Rufinamide is an antiepileptic agent whose demonstrated continuous flow synthesis 
(featuring three reactions in flow) circumvents the accumulation of toxic and explosive organoazide 
intermediates. To ascertain the feasibility and viability of this continuous synthetic route, systematic 
process modelling and costing is required. This paper presents a technoeconomic analysis of the 
upstream continuous flow synthesis of rufinamide via steady-state process modelling and plantwide 
simulation. Reaction kinetics and Arrhenius parameters are estimated from previously published 
experimental data, and plug flow reactor (PFR) volumes are calculated towards rigorous plant costing. 
Continuous reactor and separator units have been designed, and the CPM flowsheet is compared vs. 
the batch production method, with respect to technical efficiency and profitability. Plantwide costing 
via an established economic analysis methodology has been pursued to enable a detailed comparison 
of cost items towards process scale-up, as well as motivate the need for further systematic 
optimisation. 
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1. Introduction 
The pharmaceutical industry currently suffers from the highest R&D costs of all manufacturing 
sectors, significant competition from generics manufacturers, high volumes of waste and narrowing 
profit margins (Plumb 2005). Improvements in manufacturing methods can allow significant cost 
savings which could improve the profitability and sustainability of pharmaceutical firms and 
enterprises (Behr et al. 2004). Technological innovation is required to realise such improvements. 
Continuous pharmaceutical manufacturing (CPM) is a new production paradigm recognised by 
the highest regulatory levels as having the potential to allow significant reductions in environmental 
impact (Dallinger & Kappe 2017) and cost savings benefits compared to traditionally implemented 
batch methods (Poechlauer et al. 2013). Despite these benefits, with a number of demonstrated 
continuous flow syntheses (Britton et al. 2017) and end-to-end campaigns (Mascia et al. 2013; Adamo 
et al. 2016) for pharmaceutical products in the literature, there is an inertia and stagnancy to the 
widespread adoption of CPM due to existing investments in established and mature batch 
technologies (Federsel 2013). Furthermore, issues with continuous downstream processing can 
present a bottleneck to realising end-to-end CPM campaigns (Rogers & Ierapetritou 2014). Explicit 
demonstration of the benefits of CPM compared to batch methods is required to facilitate the 
transition of manufacturing paradigm. 
An important advantage of continuous operation is the ability to access process conditions (e.g. 
high pressure and temperature) that would be otherwise too hazardous to operate in batch mode 
(Movsisyan et al. 2016); this is due to the improved heat and mass transfer characteristics inherent of 
the smaller equipment dimensions required for continuous operation compared to batch vessels 
(Gutmann et al. 2015; Ashe 2012). Operating hazardous reactions is inherently safer in continuous 
mode due to the limitation of the hazard to a smaller footprint compared to equivalent setups in batch 
mode. 
Active pharmaceutical ingredients (APIs) containing 1,2,3-triazole rings are known to have a 
wide range of applications including antifungal (Aher et al. 2009), anti-HIV (da Silva et al. 2009), 
anti-cancer (Kamal et al. 2008), antibacterial (Wang et al. 2010) and tuberculosis treatments (Costa et 
al. 2006) amongst others. Synthetic routes towards molecules containing 1,2,3-triazole cores require 
generation of organoazide intermediates which pose significant operational hazards due to their high 
propensity for detonation (Badgujar et al. 2008). Such reactions in flow can potentially be too 
hazardous in batch mode due to the accumulation and required isolation of organoazide intermediates 
between batch unit operations. Continuous operation of such reactions have the potential to 
circumvent these hazards by generating these intermediates and immediately reacting them in flow 
(Baumann et al. 2011). 
Rufinamide is a societally important API developed for the treatment of Lennox-Gastaut 
syndrome (Hakimian et al. 2007), present in formulations such as Banzel or Inovelon. Rufinamide 
contains a 1,2,3-triazole ring whose synthesis requires the generation of organoazide intermediates. 
Various synthetic routes towards rufinamide have been demonstrated in recent years (Zhang et al. 
2014; Mudd & Stevens 2010; Borukhova et al. 2016; Borukhova et al. 2013; Bonacorso et al. 2015) 
with life cycle assessments also elucidating process benefits of various manufacturing routes (Ott et 
al. 2016). One of these demonstrations implements a continuous flow synthesis featuring three plug 
flow reactors (PFRs) whilst avoiding the accumulation or holdup of hazardous organoazide 
intermediates (Zhang et al. 2014). The continuous flow synthesis is followed by an antisolvent 
crystallisation implemented in batch mode. 
Experimental efforts in elucidating the best process options for CPM application can be costly and 
time-consuming; process modelling and simulation is a valid method of comparing different options 
(Teoh et al. 2015) which can establish the most feasible and viable CPM configurations. Various 
studies in the literature conduct crystallisation kinetic parameter estimation for different crystallisation 
configurations (Alvarez et al. 2011; Morris et al. 2015; Power et al. 2015; Mitchell et al. 2011; Kwon 
et al. 2015). Modelling of various conceptual crystallisation processes (Li et al. 2017; Diab & 
Gerogiorgis 2017b; Sang-Il Kwon et al. 2014) and the development of suitable control schemes for 
tuning various product characteristics (Su et al. 2015; Su et al. 2017; Nagy et al. 2013) also 
demonstrate the need for establishing promising candidate configurations prior to expensive 
experimental investigation. Integrating continuous crystallisation processes into upstream CPM plants 
is paramount for successful end-to-end implementation. 
3 
This work develops a steady-state process model for the simulation of the CPM of rufinamide 
based on the demonstrated continuous flow synthesis in the literature (Zhang et al. 2014). Reaction 
kinetic parameter regression, mass balance calculation and reactor sizing are conducted for the 
upstream CPM of rufinamide. Batch and continuous crystallisation processes following the 
continuous flow synthetic route are also modelled, implementing API solubility modelling in 
multicomponent process mixtures to systematically compare different separation options. Subsequent 
economic analyses elucidates cost savings benefits when implementing continuous crystallisation of 
the API versus the batch method. A critical discussion of the results, process modelling 
methodologies and design methods are then provided to examine the technoeconomic feasibility and 
viability of the CPM of rufinamide. 
 
2. Process Modelling and Simulation 
2.1 Process Description and Flowsheet Development 
The process model and flowsheet developed here is based on the continuous flow synthesis of 
rufinamide in a series of plug flow reactors (PFRs) demonstrated by Zhang et al. (2014). The reaction 
scheme for the CPM of rufinamide is shown in Figure 1 and the developed flowsheet in Figure 2. 
 
 
 
Figure 1: Reaction scheme for the continuous flow synthesis of rufinamide (Zhang et al. 2014).
 
 
The first reaction (in PFR-1 in Figure 2) is a SN2 substitution of 2,6-difluorobenzyl bromide (2) 
by sodium azide (NaN3) at 20 °C, forming the intermediate 2,6-difluorobenzyl azide (3) and sodium 
bromide (NaBr) as a by-product. Both reagents require dimethyl sulfoxide (DMSO) as a carrier 
solvent. The second reaction (in PFR-2 in Figure 2) features a mixture of neat methyl propiolate (4) 
and aqueous ammonium hydroxide reacting at 0 °C to form intermediate propiolamide (5), 
condensing methanol (MeOH) as a by-product. Intermediates 3 and 5 mix at a T-junction and enter 
PFR-3 (Figure 2) to synthesise the API (reaction 3) catalysed by copper reactor tubing (Zhang et al. 
2014). The original publication also reports the formation of a regioisomer of rufinamide in PFR-3, 
which is not considered here due to the lack of available kinetic data for this reaction (Zhang et al. 
2014). A back pressure of 100 psi is required to regulate NH3 gas generation (Zhang et al. 2014). The 
effluent of PFR-3 (stream F17 in Figure 2) then undergoes antisolvent crystallisation (in CR-1 in 
Figure 2) where rufinamide is crystallised and removed as a solid product (stream F19 in Figure 2). 
The mother liquor containing unreacted reagents, by-products, solvents and antisolvent is removed as 
waste (stream F20 in Figure 2). 
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Steady-state process modelling and simulation for the CPM of rufinamide assumes a plant 
capacity of 100 kg API per annum. PFR design requires reaction kinetic parameter regression and 
mass balance calculations. Process mass balances are calculated based on reported attainable 
conversion data (Zhang et al. 2014) and are scaled to account for reaction and separation 
inefficiencies to meet the specified plant capacity. The following general assumptions are made in the 
process modelling methodology: 
 
1. Reactions occur in the PFRs only and not in any associated connecting lines or units. 
2. The only reactions occurring in PFRs-1-3 are those shown in Figure 1. 
3. Isothermal operation of all PFRs is ensured by providing suitable heat transfer media and the 
selection of appropriate PFR dimensions. 
4. Temperature changes and reaction/formation of components in the process cause no phase changes 
or affect the flow, as reported by the authors of the experimental demonstration (Zhang et al. 2014). 
5. All process mixtures prior to crystallisation are homogenous and considered ideal solutions. 
 
 
 
Figure 2: Conceptual flowsheet for continuous upstream production of rufinamide (Zhang et al. 
2014).
 
Molecular weights and densities of process components are required for the conversion of stream 
flowrates for the purposes of both reactor design, calculation of API mixture solubilities and 
economic analyses. Physical properties and details of all process components described above for the 
continuous flow synthesis of rufinamide are listed in Table 1. 
 
Table 1: Process component physical properties 
Component CAS # MW (g mol-1) ρ (g mL-1) Melting Point (°C) Boiling Point (°C)
2 85118-00-9 207.02 1.63   53.50   184.90 
DMSO 67-68-5   78.13 1.10   19.00   189.00 
NaN3 26628-22-8   65.01 1.85 275.00   300.00 
3 106308-60-5 133.15 1.07 unavailable unavailable 
NaBr 7647-15-6 102.89 3.21 747.00 1390.00 
4 922-67-8   84.07 0.95 unavailable   104.05 
NH3 7664-41-7   17.03 0.77  -77.73    -33.34 
H2O 7732-18-5   18.02 1.00     0.00   100.00 
5 7341-96-0   69.06 1.10   59.50   134.60 
MeOH 67-56-1   32.04 0.79  -97.60     64.70 
API 106308-44-5 240.21 1.52 198.23   431.97 
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2.2 Reactor Design 
2.2.1 Reaction Kinetic Parameters 
Kinetic parameters are required for the design of PFRs. Reaction rate constants are calculated from 
experimental data and assumptions made are described in this section. The results and assumptions for 
kinetic parameter estimation are summarised in Tables 2 and 3. 
Reactions 1 and 2 (Figure 1) are assumed to be first-order, as they involve large organic 
molecules (2 and 4 in Reactions 1 and 2, respectively) reacting with an excess of a smaller molecules 
(NaN3 and NH3 in reactions 1 and 2, respectively). Similar assumptions of first-order reactions 
between large molecules and excesses of smaller reagents have been made in previous process 
modelling and simulation efforts (Jolliffe & Gerogiorgis, 2016a); validation of reaction order by 
comparing candidate rate law expressions for wider kinetic data sets can further validate this 
assumption. Reaction 3 involves two large organic molecules, for which we compare results 
considering reaction 3 as either first-order in 3, or overall second-order (first-order in both 3 and 5). 
Here, we describe kinetic parameter estimation methods for all three reactions. Equation 1 is the 
design equation for a PFR. 
 
τj = CA,0 න dXA– rA
,Xf,j
0
 (1)
 
Here, τj is the residence time in PFR j, CA,0 is the initial concentration of limiting reagent, Xf,j is the 
final conversion of limiting reagent in PFR j, and rA is the rate of reaction of the limiting reagent. 
Expanding and rearranging eq. 1 gives the first- and second-order rate constants in eqs. 2-3, 
respectively. 
 
k1,j	=	 1τj ln൫1–Xf,j൯	 (2)
k2,j	=	– 1τjCA,0 න
dXA
ሺ1–XAሻሺΘB	+	ϑBXAሻ
Xf,j
0
 (3)
 
ki,j is the ith order rate constant of the reaction occurring in PFR j, ΘB is the molar ratio of excess 
reagent to the limiting reagent and νB is the stoichiometric coefficient of excess reagent. The integral 
in eq. 3 is calculated in MS Excel for reported attainable conversions. Eqs. 2-3 allow calculation of 
reaction rate constants from reported attainable reaction conversions at certain PFR residence times 
and reagent stoichiometries implemented in the literature (Zhang et al. 2014). 
In reaction 1, 1.3 equivalents of NaN3 react with 2 to form 3, with a reported conversion of 2 of 
100% at room temperature for a residence time of 1 min (Zhang et al. 2014); for modelling purposes, 
the conversion of 2 has been taken to equal 99.99%. The first-order rate constant of reaction 1 is 
estimated as k1,1 = 9.21 min-1 using eq. 1 (Table 2). 
Reaction 2 involves 4 equivalents of NH3 reacting with 1 equivalent of 4; the reported conversion 
of 4 is 95% at 0 °C for a residence time of 5 min (Zhang et al. 2014). The first-order rate constant of 
reaction 2 was estimated to be k1,2 = 0.60 min-1 using eq. 1 (Table 2). 
 
Table 2: Kinetic parameter estimation results for reactions in PFRs 1 and 2. 
 PFR j 
 1 2 
Reaction 2 + NaN3  3 4 + NH3  5 + MeOH 
Reaction Order, i 1 1 
Rate Law –rA = k1,1CA –rA = k1,2CA 
Reactor temperature, Tj (°C) 20 0 
Final conversion, Xf (%)    99.99  95 
First-order rate constant, k1,j (min-1)      9.21      0.60 
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Figure 3 summarises attainable API yields at varying temperatures for reaction 3 (T3) reported in 
for the continuous flow synthesis of rufinamide (Zhang et al. 2014). Attainable API yield decreases 
beyond a certain temperature due to formation of an API regioisomer. We have fitted a third-order 
polynomial to the experimental API yield-temperature data, from which the temperature 
corresponding to the maximum API yield is estimated; this temperature is 117 °C with a maximum 
API yield of 99.56% (see Figure 3). Below T3 = 117 °C, it is assumed that only the desired reaction 
occurs (reaction 3, Figure 1). We calculate first- and second-order rate constants for reaction 3 at 
temperatures of 90, 110 (considered in the literature) and 117 °C, for which we assume that the only 
reaction occurring in PFR-3 is reaction 3 (Figure 1). 
 
 
 
 
Figure 3: API yield in PFR-3 reported by Zhang et al. (2014) as a function of reaction temperature, 
T3. 
 
 
In reaction 3, 1 equivalent of 3 reacts with 1.42 equivalents of 5 to form rufinamide (API). First- 
and second-order reaction rate constants were estimated using eqs. 2-3 from attainable conversions of 
83%, 98% and 99.56% at operating temperatures (T3) of 90, 110 and 117 °C, respectively, all for 
residence times of 6.47 min  (Zhang et al. 2014). First- and second-order reaction rate constants for 
reaction 3 are listed in Table 3. 
The Arrhenius law (eq. 4) describes the temperature-dependency of reaction rate constants. 
 
ki,j൫Tj൯	=	A expቆ– EaRTjቇ (4)
 
where A is the pre-exponential factor, Ea is the reaction activation energy and R is the universal gas 
constant. Values of A and Ea can be estimated from calculated first- and second-order rate constants at 
different temperatures in PFR-3; these values are provided in Table 3. 
 
Table 3: Reaction kinetics and Arrhenius parameter estimation results for the reaction in PFR 3. 
Reaction 3 + 5  API 
PFR 3: T3 (°C) 90 110 117 
XA (%) 83 98 99.56 
Reaction Order 1 2 1 2 1 2 
Rate Law –rA = k1,3CA –rA = k2,3CACB –rA = k1,3CA –rA = k2,3CACB –rA = k1,3CA –rA = k2,3CACB
CA,0 (M) n.r. 0.248 n.r. 0.248 n.r. 0.248 
ki,j (units) 0.27 (min-1) 1.34 (M-1 min-1) 0.60 (min-1) 3.51 (M-1 min-1) 0.79 (min-1) 4.85 (M-1min-1)
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A (—) 1.06 ∙106 1.28 ∙ 108 1.06 ∙ 106 1.28 ∙ 108 1.06 ∙ 106 1.28 ∙ 108
Ea (J mol-1) 4.58 ∙ 104 5.55 ∙ 104 4.58 ∙ 104 5.55 ∙ 104 4.58 ∙ 104 5.55 ∙ 104 
 
The operating temperature of PFR-3 (T3) affects the reaction conversion, which alters the process 
mass balances and total costs of different process designs. We compare the effect of the operating 
temperature (T3 = 90, 110 and 117 °C) and the assumed order of reaction 3 (first- and second-order) 
on process modelling results. 
 
2.2.2 Plug Flow Reactor Design 
Reactor volumes are calculated from the required residence time and the material throughput required 
to attain the specified plant capacity (100 kg API per annum): 
Vj	= τjQj (5)
 
where Vi and Qi are the volume and volumetric flowrate of PFR j, respectively.  
 
2.3 Crystallisation Design 
The modelling of crystallisation processes requires API solubility data in multicomponent mixtures. 
Very limited data for rufinamide solubilities in pure components or mixtures exist in the literature; the 
experimental solubility of rufinamide in pure DMSO and water at 25 °C (mole fraction solubility = 
0.014) is available (Food and Drug Admnistration 2006). Theoretical methods for drug solubility 
estimation in pure solvents and multicomponent mixtures can be implemented (Bouillot et al. 2011), 
however essential interaction parameters for even the most established models (UNIFAC, NRTL, 
NRTL-SAC, COSMO-SAC) are unavailable. A correlation between the octanol-water partition 
coefficient (ln Kow = -0.12) and the API molar volume (Vm = 212.47 cm3 mol-1) estimates the API 
solubility in water (Miller et al. 1985): 
 
ln CAPIsat 	=	a	 െ 	bVm െ ln KOW + ln F (6)
F	= 	exp ൬ΔS
R
൰ ൬1 െ Tcryst
Tm
൰ (7)
ΔS
R
	≈	6.8 (8)
 
where CAPIsat is the solute solubility in water (mol m-3), F is the fugacity ratio, ΔS is the entropy of 
fusion and Tm is the melting point of the API (see Table 1). a and b are model parameters (a = 3.9 ± 
0.2, b = 0.005 ± 0.001). ΔS/R is taken as 6.8 when data for entropy of fusion is unavailable (Miller et 
al. 1985). Kow is a function of temperature; a correlation between Kow and temperature is unavailable, 
so all crystallisation processes are modelled at Tcryst = 25 °C. 
The API solubility in the mixture is calculated as the sum of mole fraction weighted API 
solubilities in DMSO (carrier solvent) and water (antisolvent), respectively. 
 
S	API	mix 	=	x	DMSO	mix S	API	DMSO	+	x H2Omix S	API	H2O (9)
 
where SAPI is the API mole fraction solubility in a pure solvent or mixture and xi is the mole fraction 
of carrier-/antisolvent in the multicomponent mixture. This method allows the comparison of 
candidate antisolvent crystallisation processes using water as an antisolvent. 
The crystallisation yield of API is calculated from the feed API mole fraction and the API mole 
fraction solubility at saturation 
 
Yi	=	100ቆ1 െ SAPI
mix
xAPI
feedቇ (10)
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where Yi is the API crystallisation yield and xAPIfeed is the API mole fraction in the effluent of PFR-3 
fed to the crystalliser (CR-1). The method described by eqs. 6-10 was validated by reproducing the 
experimental batch crystallisation yield of rufinamide within 1%. 
In all cases, the effluent of PFR-3 is considered a binary mixture of DMSO and water (single 
phase) in which all stream components (API, unreacted reagents, byproducts) are considered 
dissolved solutes. The original continuous flow synthesis publication for rufinamide reports direct 
batchwise antisolvent crystallisation from the effluent of PFR-3 using water as an antisolvent at an 
antisolvent-to-feed ratio (AS:F, by mass) of 1.83, with a total crystallisation residence time of 75 min 
(Zhang et al. 2014). Here, we compare the continuous flow synthesis of rufinamide with the 
demonstrated batch crystallisation route to that with a conceptual continuous crystallisation method 
also using water as an antisolvent. For the modelling of continuous crystallisation, we consider 
antisolvent-to-feed ratios (AS:F, by mass) of 0.25-5 to investigate the effect of varying antisolvent 
usage. A crystalliser residence time of 60 min is assumed for all CPM processes and a factor of 90% 
is applied to consider the non-attainment of thermodynamic equilibrium in steady-state (continuous) 
processes. Crystalliser volumes (Vcryst) for CPM processes are calculated from the crystalliser 
residence time (τcryst) and the total volumetric flowrate through the crystalliser (Qcryst). 
 
Vcryst	=	τcrystQcryst (11)
 
2.4 Environmental Impact Analysis 
Ensuring inherently green process designs is essential to ensure low environmental impacts. Recent 
efforts show significant process improvements in decreasing the quantity of waste produced by a 
continuous flow synthetic route (Bédard et al. 2016). The environmental impacts of different process 
options are compared by quantifying green chemistry metrics. Here, we compare the process mass 
intensities (PMIs) and mass productivities (MPs) of different process options. The PMI quantifies the 
material input required to produce a unit of material output (Jimenez-Gonzalez et al. 2011): 
 
PMI	=	minput
mAPI
	=	mreagents +	msolvents	+	mantisolvents
mAPI
 (12)
 
where mreagents is the total mass of reagents required, msolvents is the mass of carrier solvents (DMSO for 
reaction 1, H2O for reaction 2), mantisolvent is the mass of antisolvent (H2O) used for crystallisation and 
mAPI is the mass of recovered (crystallised) API. The mass productivity (MP) is another commonly 
used metric which quantifies how efficiently material is used in a process (Sheldon 2012): 
 
MP	=	 100
PMI
 (13)
 
PMIs and MPs are calculated for all batch and CPM processes. For CPM processes, a solvent 
recovery (carrier and anti-solvents) of 70% is assumed in accordance with previous work (Jolliffe & 
Gerogiorgis 2016b). 
Green chemistry metrics considered here (PMI and MP) are calculated based on the mass of 
crystalline API obtained only, assuming ideal product purity (100% API). An understanding of 
impurity component distribution (for which parameters are not available for this specific process) can 
inform process design for maximum crystal purity (Li et al. 2017). Purification of the effluent of the 
final PFR prior to continuous crystallisation may be necessary in practice; this may incur additional 
material requirements that must be included in green chemistry metric calculation. Additional design 
measures to ensure other desired product attributes, such as crystal size and shape, should also be 
included and incorporated into comprehensive life-cycle assessment (LCA) studies. 
 
2.5. Economic Analysis 
Elucidating cost benefits of CPM over batch technologies is paramount in demonstrating the viability 
of continuous manufacturing methods (Cervera-Padrell et al. 2012). Our recent work (Jolliffe & 
Gerogiorgis 2017a; Jolliffe & Gerogiorgis 2017b; Diab & Gerogiorgis 2017a) has implemented a 
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methodology for the economic analysis of pharmaceutical processes (Schaber et al. 2011). All 
processes are implemented at an existing pharmaceutical manufacturing site with essential auxiliary 
infrastructures already in place. 8,040 hours of annual operation are considered in this work. 
 
2.5.1 Capital Expenditure (CapEx) 
Prices for equipment of similar capacities to those in this work have been sourced; a cost-capacity 
correlation is used where equipment of different capacities are found (Woods 2007): 
 
CB	=	f	CA ൬SBSA൰
n
 (14)
Cj is the equipment purchase cost at capacity Sj. Parameters n and f account for varying design 
considerations and are found in the literature (Woods 2007). Where the reference purchase cost (CA) 
is taken from the past, chemical engineering plant cost indices (CEPCIs) are used to account for 
inflation. All equipment capacities are scaled to account for PFR and crystalliser inefficiencies to 
meet the plant capacity. PFRs are priced as microreactors (Corning 2015); solenoid pumps 
(ProMinent 2015),  coolers (Cole-Parmer 2015) and crystalliser (Woods 2007) prices are sourced 
from historical data. The sum of all inflation-adjusted equipment purchase costs gives the Free-on-
Board (FOB) cost. Tables 4 and 5 provide purchase costs and scaling parameters in eq. 14 and the 
FOB components and total costs for different assumptions of reaction order in PFR-3. 
 
Table 4: Free-On-Board (FOB) costs assuming the reaction in PFR 3 is first-order.  
Batch (PFR-3: T3 = 110 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   4.33   5,207   5,207 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.37   4,055   4,055 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 31.63 38,069 38,069 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 — —   3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 1.11 ∙ 10-3        85        85 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5        958 — —     958   4,790 
FOB (GBP) 59,114 
CPM (PFR-3: T3 = 90 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80    4.89   5,884   5,884 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.81   4,582   4,582 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 36.28 43,662 43,662 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 — —   3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 1.07 ∙ 10-3        83        83 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 — —     958   4,790 
FOB (GBP) 65,908 
CPM (PFR-3: T3 = 110 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   4.06 4,890   4,890 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.16 3,807   3,807 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 30.15 36,285 36,285 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 — — 3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 8.88 ∙ 10-4 73        73 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 — — 958   4,790 
FOB (GBP) 56,753 
CPM (PFR-3: T3 = 117 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.99   4,805    4,805 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.11   3,742    3,742 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 29.63 35,659  35,659 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 — —   3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 8.73 ∙ 10-4        72        72 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 — —      958   4,790 
FOB (GBP) 55,976 
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The Chilton method is used to calculated the Battery Limits Installed Cost (BLIC)(Couper 2003). 
The installed equipment cost (IEC) is 1.43 times the FOB. Process piping and instrumentation (PPI) 
costs are 42% of IEC, respectively. The sum of IEC and PPI gives the total physical plant cost 
(TPPC). A construction factor of 0.3 is added to the TPPC to calculate the BLIC. 
 
IEC = 1.43FOB (15)
PPI = 0.42IEC (16)
TPPC = IEC + PPI (17)
BLIC = 1.3TPPC (18)
Working capital costs are taken as 35% and 3.5% of annual material costs (MATannual, assuming 
70% solvent recovery for CPM processes) for batch and CPM processes, respectively. Annual 
material costs for batch processes have an added factor of 60% to account for labour and handling 
(Schaber et al. 2011). Contingency costs (CC) are calculated as 20% of the BLIC. The sum of 
working capital and contingency costs (WCC) and BLIC gives the total capital expenditure (CapEx) 
of the process. 
 
WC = ൜	0.350MATannual , batch0.035MATannual  , CPM (19)
CC = 0.2BLIC (20)
WCC = WC + CC (21)
CapEx = BLIC + WCC (22)
 
Table 5: Free-On-Board (FOB) costs assuming the reaction in PFR 3 is second-order.  
Batch (PFR-3: T3 = 110 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   4.33   5,207   5,207 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.37   4,055   4,055 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 33.84 40,721 40,721 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 — -   3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 1.11 ∙ 10-3        85        85 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 — -      958   4,790 
FOB (GBP) 61,766 
CPM (PFR-3: T3 = 90 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   4.89   5,884   5,884 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.81   4,582   4,582 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 38.80 46,699 46,699 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 —    3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 1.07 ∙ 10-3       83        83 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 —       958   4,790 
FOB (GBP) 68,946 
CPM (PFR-3: T3 = 110 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   4.06   4,890   4,890 
PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.16   3,807   3,807 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 32.25 38,812 38,812 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 —    3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 8.88 ∙ 10-4        73        73 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 —       958   4,790 
FOB (GBP) 59,280 
CPM (PFR-3: T3 = 117 °C) 
  Type Year CEPCI f Basis n # Units CA (GBP) SA SB CB (GBP) Total (GBP)
PFR-1 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.99   4,805   4,805 
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PFR-2 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80   3.11   3,742   3,742 
PFR-3 Reactor 2014 578.4 1.0106 Vi (mL) 1.00 1 103,208 80 31.69 38,142 38,142 
HX-1-2 Cooler 2015 543.0 1.0000 — 1.00 2     3,454 —    3,454   6,908 
CR-1 Crystalliser 2007 525.4 1.1033 Vcryst (m3) 0.68 1 146,250 75 8.73 ∙ 10-4        72        72 
P1-5 Pump 2015 543.0 1.0000 — 1.00 5       958 —       958   4,790 
FOB (GBP) 58,459 
2.5.2 Operating Expenditure (OpEx) 
Material purchase prices are sourced from various vendors (Table 6). All material requirements are 
scaled to account for plantwide inefficiencies to meet the specified plant capacity (100 kg per annum) 
and provided in Table 6. Annual utilities costs (UTILannual) are calculated as 0.96 GBP kg-1 of 
material. Annual waste costs (Wasteannual) are 0.35 GBP L-1 of waste carrier- and anti-solvent. 
 
UTILannual = 0.96MATannual (23)
Wasteannual = 0.35 ൬m20
DMSO
ρDMSO
+	 m20H2OρH2O൰ ሺ1 െ SRሻ (24)
U&Wannual = UTILannual + Wasteannual (25)
 
where m20DMSO and m20H2O are the mass flowrates of DMSO and water in waste stream F20, 
respectively (Figure 2), and SR is the solvent recovery (70% for CPM processes). 
 
Table 6: Material requirements of the process with batch and CPM crystallisation methods for 
varying design assumptions (operating temperature of PFR-3, T3). 
T3 (°C)
Batch (kg y-1) CPM (kg y-1) Price (GBP kg-1) 
110 90 110 117 
2 115           130 108 106        2,560.00 
DMSO           2,137           724 602 592    2.31 
NaN3  45 51   42   42           541.00 
4  70 79   66   64        4,649.00 
NH3  57 64   53   64    0.19 
H2O           4,985        1,846          1,534        1,507    0.60 
Total           7,409        2,893          2,405        2,375  
 
2.5.3 Total Costs 
Total material (MATtotal) and utilities and waste (U&Wtotal) costs are calculated as the inflation-
adjusted annual material and U&W costs, respectively. Total operating expenditure (OpExtotal) is 
taken as the sum of total material and U&W. 
 
MATtotal= ෍ MATannualሺ1	+	rሻk
τ
k	=	1
 (26)
U&Wtotal= ෍ U&Wannualሺ1	+	rሻk
τ
k	=	1
 (27)
OpExtotal = MATtotal + U&Wtotal (28)
 
A total plant-operating lifetime (τ) of 20 years and an interest rate (r) of 5% are considered. The 
total cost of the plant designs is calculated as the sum of CapEx and inflation-adjusted OpEx over the 
plant lifetime. 
 
Total Costs = CapEx + OpExtotal (29) 
 
All CapEx is assumed to occur in year 0 and operation is assumed to begin in year 1. 
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3. Results and Discussion 
3.1 Mass Balances 
The calculated mass balances are based on the process for the continuous flow synthesis of rufinamide 
(API) described by Zhang et al. (2014). Component mass flowrates of key flowsheet streams (Figure 
2) for all considered operating temperatures of PFR-3 (T3 = 90, 110 and 117 °C) are shown in Figure 
4; these streams are the feed to PFR-1 (F8), PFR-2 (F14) and PFR-3 (F16) and the effluent of PFR-3 
(F17) prior to crystallisation. All streams have been scaled to account for reaction and crystallisation 
inefficiencies to the meet the specified plant capacity (100 kg API per annum). 
For all CPM process variations (different considerations of the operating temperature of PFR-3), 
DMSO (the carrier solvent in PFR-1) contributes a significant portion of the total mass balance 
throughout the whole process. Reagents for reaction 1 in PFR-1 (2 and NaN3) are nearly negligible in 
streams following PFR-1 (F16 and F17 in Figure 2) due to the high attainable conversion (99.99% 
assumed here). Similarly, the reagents for reaction 2 and PFR-2 (4 and NH3) are in trace quantities 
following PFR-2 due to the high conversion attained in the reactor. Due to these high conversions, 
there are significant quantities of desired intermediates (3 and propiolamide) and by-products (NaBr 
and MeOH) in the feed to PFR-3 (F16 in Figure 2). Rufinamide (API) is present in significant 
quantities due to the high conversions attained at all PFR-3 operating temperatures (T3) considered 
and to account for subsequent crystallisation inefficiencies. 
 
 
Figure 4: Process mass balances of key flowsheet streams for the CPM of rufinamide under different 
considerations of the operating temperature of PFR 3 (T3). 
 
 
3.2 Plug Flow Reactor Design 
PFR volumes are calculated (Figure 5) from required reaction residence times to meet reported 
attainable conversions and material throughputs calculated from process mass balances. Small reactor 
volumes are calculated for PFRs-1 and 2 for all PFR-3 operating temperatures (T3) considered; this is 
due to the high attainable conversions (99.99% and 95% in PFRs-1 and 2, respectively) short 
residence times (1 and 5 min for PFRs-1 and 2, respectively) and low material throughputs required to 
meet the desired plant capacity. Computed volumes for PFR-3 for all considered operating 
temperatures (T3) and both reaction order assumptions are higher due to the higher material 
throughput and longer residence time (6.47 min) required to reach the target attainable conversions 
compared to the previous PFRs. 
Appropriate choice of the internal diameter of PFRs (di) is an important design parameter for the 
resulting reactor length as well as ensuring negligible axial temperature and concentration gradients 
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(Roberge et al. 2005). Here, we consider PFR inner diameters of 2.5–15.0 mm, in accordance with 
reported microreactor applications (Wilms et al. 2009; Mascia et al. 2013). Resulting reactor lengths 
for different inner diameters are shown in Figure 6 for all PFR-3 design variations. Reactor lengths 
vary from very small (< 10 cm) to considerable sizes (< 750 cm). Reactors of significant length can be 
coiled in order to reduce the overall equipment size and maintain the benefit of small plant footprint 
available via continuous operation (Mascia et al. 2013; Ashe 2012; Kopetzki et al. 2013). 
Figures 5 and 6 show only a small difference in PFR volumes and lengths between different 
considerations of first- and second-order assumptions for reaction 3. It is important to note that these 
results neglect the undesired side reaction forming a regioisomer of rufinamide in PFR-3, which will 
affect the results presented here. It has been assumed that only the desired reaction occurs in PFR-3 
for the operating temperatures considered in this work. Kinetic data for this side reaction is required to 
estimate accurate reactor volumes and dimensions. 
 
 
Figure 5: PFR volumes for different assumptions of temperature and reaction order in PFR-3. 
 
 
3.3 Crystallisation Design 
Calculated API mixture solubilities and attainable crystallisation yields for continuous crystallisation 
of rufinamide from the effluent of PFR-3 (F17 in Figure 2) using water as an antisolvent are shown in 
Figure 7. Antisolvent-to-feed ratios (AS:F, by mass) of 0.25-5 are considered for continuous 
crystallisation from the effluents of PFR-3 for all operating temperatures of PFR-3 considered. In all 
cases, increasing AS:F decreases the API mixture solubility and thus increases the attainable 
crystallisation yield. Non-attainment of thermodynamic (solid-liquid) equilibrium when operating in 
continuous crystallisation mode is accounted for by applying a factor of 90% to all attainable yields. 
Beyond AS:F = 2, the crystallisation yield only increases incrementally, and thus the increased 
antisolvent usage and resulting crystalliser volumes will lead to unnecessary increases in CapEx, 
OpEx and PMIs (implying greater quantities of waste to treat). For this reason, continuous 
crystallisation processes using AS:F = 2 is chosen for all  subsequent economic analyses. 
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Figure 6: PFR lengths for varying inner diameters (di) for different assumptions of the temperature 
and reaction order in PFR 3. 
 
 
 
Figure 7: API mixture solubility and attainable crystallisation yield as a function of antisolvent usage 
and operating temperature of PFR-3 (T3). 
 
 
3.4 Environmental Impact Analysis 
Process mass intensities (PMIs) and mass productivities (MPs) for the batch process and varying 
CPM process considerations (different PFR-3 operating temperatures, T3) are shown in Figure 8. CPM 
process options consider 70% recovery of carrier- and anti-solvent following continuous 
crystallisation; AS:F = 1.83 for batch crystallisation (Zhang et al. 2014) and AS:F = 2 for all 
continuous crystallisations. As the operating temperature in PFR-3 (T3) increases, PMIs decrease and, 
correspondingly, MPs increase due to the increased plantwide API recoveries attainable as the 
conversion in PFR-3 increases. PMIs of typical pharmaceutical processes can be as high as 200 due to 
the inherent complexity of required manufacturing stages involving multistep syntheses, intermediate 
workups and purifications etc. (Ritter 2013). These results show the significant improvements in 
material efficiency and reduction in environmental impact available via CPM implementation from 
the improved green chemistry metrics compared to the batch process, as shown in Figure 8. 
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Figure 8: Process mass intensities (PMIs) and mass productivities (MPs) of the process with batch 
and continuous crystallisation options for different assumptions of the operating temperature of PFR 3 
(T3). 
 
3.5 Economic Analysis 
Unit capacities and material requirements are scaled to account for reaction and crystallisation 
inefficiencies to meet the specified plant capacity (100 kg API per annum). A comparison between 
different total cost components between processes with a batch crystallisation process and a 
continuous crystallisation from the effluent of PFR-3, considering different operating temperatures of 
PFR-3 (T3). The batch crystallisation process uses AS:F = 1.83 and all continuous crystallisations use 
AS:F = 2 with an assumed 70% recovery of carrier- and antisolvents. Table 7 shows the calculated 
cost components and differences between batch and CPM process variations. 
  
Table 7: Cost components (103 GBP) and differences between batch and CPM processes for different operating 
temperatures in PFR 3 (T3). 
PFR 3 = 1st order 
 Batch CPM (AS:F = 2; SR = 70%) 
T3 (°C) 110 90 110 117 
 Cost Cost Difference Cost Difference Cost Difference 
BLIC 156 174 +11.5% 150   –4.0% 148   –5.3% 
WCC 396   60 –84.8%   51 –87.1%   50 –87.3% 
CapEx 552 234 –57.5% 201 –63.6% 198 –64.1% 
10-1 ∙ Materials     1,298 909 –30.0% 909 –30.0% 909 –30.0% 
10-1 ∙ U&W     1,249 874 –30.1% 874 –30.1% 874 –30.1% 
10-1 ∙ OpEx     2,547     1,783 –30.0%      1,783 –30.0%      1,783 –30.0% 
Total   26,020   18,060 –30.6%    18,027 –30.7%    18,024 –30.7% 
PFR 3 = 2nd order 
 Batch CPM (AS:F = 2; SR = 70%) 
T3 (°C) 110 90 110 117 
 Cost Cost Difference Cost Difference Cost Difference 
BLIC 163 182 +16.6% 156 +0.3% 154 –1.1% 
WCC 397 62 –84.4% 53 –86.7% 52 –86.9% 
CapEx 560 244 –55.8% 209 –62.1% 206 –62.7% 
10-1 ∙ Materials     1,298 909 –30.0% 909 –30.0% 909 –30.0% 
10-1 ∙ U&W     1,249 874 –30.1% 874 –30.1% 874 –30.1% 
10-1 ∙ OpEx     2,547 1,783 –30.0% 1,783 –30.0% 1,783 –30.0% 
Total   26,028 18,069 –30.6% 18,035 –30.7% 18,032 –30.7% 
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BLIC savings are only attainable for T3 = 110 and 117 °C when a first-order reaction in PFR-3 is 
considered, and only for T3 = 117 °C when a second-order reaction in PFR-3 is considered. This is 
due to the higher plantwide API recoveries attainable when implementing a batch crystallisation 
compared to the continuous crystallisation when PFR-3 is operated at lower temperatures; lower 
recoveries require increased material throughputs to meet the plant capacity and thus larger 
equipment. WCC costs are significantly lower for all continuous options considered due to the 
significantly lower solvent requirements due to the solvent recovery option considered for CPM as 
well as the additional labour and handling requirements of the batch process. Correspondingly, both 
material and U&W costs are significantly lower for all CPM options compared to the process 
implementing batch crystallisation. 
CapEx, OpEx and total cost savings of CPM options relative to the process implementing batch 
crystallisation for varying PFR-3 design assumptions are shown in Figure 9. It is shown that varying 
the operating temperature in PFR-3 (T3) and different assumptions of reaction order (first- or second-
order) have little effect on the calculated total cost components. CapEx savings variations across 
different design options are observed due to the effect of PFR-3 operating temperature (T3) on 
conversion, and thus plantwide API yield, which directly affects the required material throughput and 
unit sizes. OpEx costs show little variation for each PFR-3 operating temperature (T3) chosen for first- 
and second-order reaction assumptions (in PFR-3) due to similar mass balances and identical solvent 
recoveries (70%). Thus, there is little variation in total cost savings for different design assumptions 
for PFR-3. This shows that the reaction order in PFR-3 has only a slight effect on the CPM process.  
Nevertheless, it is imperative to make informed decisions from detailed kinetic data to present 
accurate cost components for different process options. 
 
 
 
 
Figure 9: Cost savings of implementing a continuous crystallisation process relative to implementing 
a batchwise crystallisation. 
 
 
4. Conclusions 
Rufinamide is a societally important API that requires materially efficient and economically viable 
manufacturing methods. This work has developed a steady-state process model for the CPM of 
rufinamide for a plant capacity of 100 kg per annum. The model is based upon a published continuous 
flow synthetic route featuring three plug flow reactors for the synthesis of the API (Zhang et al. 2014) 
which circumvents the accumulation or isolation of hazardous intermediate organoazides required for 
the generation of molecules containing 1,2,3-triazole rings. The demonstrated route features short 
residence times and high conversions towards rufinamide. 
The technoeconomic evaluation conducted in this work features kinetic parameter estimation for 
different assumptions of the reaction order in the final PFR, reactor sizing based on mass balance 
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calculations and the desired API plant capacity for different operating temperatures of the final PFR, 
comparison of batch and continuous crystallisation routes via API solubility modelling in 
multicomponent mixtures (Miller et al. 1985) and economic analyses to establish cost savings 
attainable when implementing a continuous crystallisation with respect to the batch crystallisation. 
The process modelling and technoeconomic evaluation follow published methodologies for a new 
API for which process modelling has not been previously conducted. 
Small PFR volumes and lengths for the specified plant capacity are computed for all process 
design variations (different assumptions on the reaction order in the final PFR and its operating 
temperature), demonstrating a clear CPM advantage. Calculated crystallisation yields for varying 
extents of antisolvent usage account for non-attainment of thermodynamic equilibria typical of 
steady-state (continuous) operation. Environmental impacts of different process options are compared 
via two popular green chemistry metrics (the process mass intensity, PMI, and the mass productivity, 
MP) which quantify the material efficiency of manufacturing processes; results show a significant 
reduction in environmental impact when implementing a continuous crystallisation method compared 
to the batch crystallisation (lower PMIs and higher MPs). Cost estimations follow an established 
methodology for batch and continuous pharmaceutical processes (Schaber et al. 2011) and show 
significant total cost savings when implementing a continuous crystallisation process with respect to 
the batch crystallisation route. Various assumptions in our process modelling methodology affect 
these results (e.g. extent of solvent recovery, various costing considerations etc.) but they have been 
documented in this work to allow reproducibility and to allow future sensitivity analyses of various 
design parameters. 
The process modelling and simulation for the CPM of rufinamide demonstrated in this work 
shows the importance of conducting such conceptual studies for pharmaceutical processes prior to 
further development and scale-up. The results demonstrate the environmental and economic benefits 
of continuous operation for the manufacturing of this societally important API. The potential for a 
scaled-up application of this process must be further developed by considering its implementation 
when integrated with subsequent essential downstream unit operations. Subsequent technoeconomic 
optimisation via non-linear programming with detailed experimental data (including kinetics for side 
reactions described in the continuous flow synthesis experimental publication) can elucidate the best 
operating parameters and process configurations for CPM implementation. 
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6. Nomenclature and Acronyms 
Latin Letters and Acronyms 
a Parameter in eq. 6 
A Pre-exponential factor in Arrhenius law (–) 
API Active pharmaceutical ingredient 
AS:F Antisolvent-to-feed ratio by mass (F18:F17 in Figure 2) 
b Parameter in eq. 6 
BLIC Battery limits installed costs (GBP) 
CA Concentration of limiting reagent (M) 
CA,0 Initial concentration of limiting reagent (M) 
CAPIsat API saturation concentration in water (mol m-3) 
Ci Purchase cost of equipment at capacity i (GBP) 
CapEx Capital expenditure (GBP) 
CC Contingency costs (GBP) 
CEPCI Chemical engineering plant cost index 
CPM Continuous pharmaceutical manufacturing 
di PFR inner diameter (mm) 
DMSO Dimethyl sulfoxide 
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Ea Activation energy of reaction j (J mol-1) 
F Fugacity ratio (–) 
f Correction factor in eq. 14 
FOB Free-on-board costs (GBP) 
IEC Installed equipment costs (GBP) 
ki,j ith order rate constant of the reaction in PFR j (min-1 or M-1min-1) 
KOW API octanol-water partition coefficient (–) 
LCA Life-cycle assessment 
mji Mass flowrate of component i in stream j in Figure 2 (kg y-1) 
mantisolvent Mass of antisolvent fed to the process (kg y-1) 
mAPI Mass of API produced (kg y-1) 
minput Mass of material input through the process (kg y-1) 
mreagents Mass of reagents fed to the process (kg y-1) 
msolvent Mass of carrier solvent fed to the process (kg y-1) 
MATannual Annual material costs (GBP y-1) 
MATtotal Total material costs over the plant lifetime (GBP) 
MeOH Methanol 
MP Mass productivity (%) 
MW Molecular weight (g mol-1) 
n Exponent in eq. 14 
OpExtotal Total operating expenditure over the plant lifetime (GBP) 
PFR Plug flow reactor 
PMI Process mass intensity (–) 
PPI Process piping and instrumentation costs (GBP) 
Qcryst Volumetric flowrate through the crystalliser (mL min-1) 
Qj Volumetric flowrate through PFR j (mL min-1) 
R Universal gas constant (= 8.314 J mol-1 K-1) 
r Interest rate (%) 
rA Rate of reaction of limiting reagent (M min-1) 
SAPIj API mole fraction solubility in solvent j (–) 
Sj Capacity of equipment (varying units) 
ΔS Entropy of fusion (J mol-1 K-1) 
SR Solvent recovery (%) 
Tcryst Crystallisation temperature (25 °C) 
Tj Operating temperature of PFR j 
Tm API melting point (°C) 
TPPC Total physical plant cost (GBP) 
U&Wannual Sum of annual annual utilities and waste disposal costs (GBP y-1) 
U&Wtotal Total utilities and waste disposal costs over the plant lifetime (GBP) 
UTILannual Annual utilities costs (GBP y-1) 
Vj Volume of PFR j (mL) 
Vcryst Crystalliser volume (mL) 
Vm API molar volume (cm3 mol-1) 
WC Working capital costs (GBP) 
WCC Working capital and contingency costs (GBP) 
XA Conversion of limiting reagent (%) 
Xf Final attainable conversion of limiting reagent (%) 
xi Mole fraction of component i (–) 
Yi Crystallisation yield (%) 
  
Greek letters 
ΘB Mole ratio of excess reagent to limiting reagent (–) 
νB Stoichiometric coefficient of excess reagent (–) 
ρi Density of component i (g mL-1) 
τcryst Crystalliser residence time (min) 
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τj Residence time in PFR j (min) 
τ   Plant lifetime (y) 
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